Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In a nonhuman primate model of Zika virus infection, structural and cellular pathology deficits that could have a long-lasting impact on neural development and neurocognitive function are detected in offspring of infected mothers.
An active immunosuppressive pathway is identified in colon cancer that confers immune evasion by the cancer and can be targeted to synergize with immunotherapies.
Studies in metastatic melanoma, non-small-cell lung carcinoma and renal cell carcinoma indicate certain bacteria within the gut microbiota enhance clinical responses to checkpoint blockade.
Genomic and drug screens identify SHP2 blockade as a therapeutic approach for ALK-rearranged non-small cell lung cancers developing resistance through ALK-mutant-independent mechanisms.
A preclinical therapy to treat neurodegeneration is developed that selectively targets the AF-2 domain of the androgen receptor while sparing other functions of this receptor.
Mass cytometry of diagnostic biopsies from children with B cell precursor acute lymphoblastic leukemia identifies a signaling state that predicts relapse.
In a nonhuman primate model of spinal cord injury, human neural progenitor cell grafts exhibit long-term survival, differentiation, and anatomical integration with host spinal circuitry.
The small molecule H3B-8800 selectively modulates RNA splicing to preferentially kill tumor cells bearing mutations in genes encoding spliceosome components.
The conserved long noncoding RNA MeXis has anti-atherosclerotic effects in mice by acting with the nuclear hormone receptor LXR in macrophages to promote cholesterol efflux.
Combining the kinase inhibitor sorafenib with allogeneic stem cell transplantation boosts immune responses against a subtype of acute myelogenous leukemia, suggesting potential clinical benefit.
A recent study investigates the contribution of epigenomic plasticity to lung metastasis in osteosarcoma. Changes in the enhancer landscape were found to be nonrandom and driven by selective forces in the microenvironment.